Señales en vivo de IDYA | Maximiza tus Ganancias con Getagraph.com

VENDER 112396 min ago

@ $45.58

Emitido: 14 feb 2024 @ 09:32

Retorno: -8.62%

Señal anterior: feb 13 - 15:04

Señal anterior: Comprar

Retorno: 1.54 %

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 11:47):

Stats
Volumen de hoy	143 223
Volumen promedio	718 311
Capitalización de mercado	3.11B
EPS	$0 ( 2024-03-05 )
Próxima fecha de ganancias	( $-0.530 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.25
ATR14	$0.0750 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Hata Yujiro S	Buy	480 000	Stock Option (right to buy)
2024-03-01	Ruiz Briseno Andres	Buy	85 000	Stock Option (right to buy)
2024-03-01	Beaupre Darrin	Buy	160 000	Stock Option (right to buy)
2024-03-01	White Michael Anthony	Buy	140 000	Stock Option (right to buy)
2024-03-01	Throne Jason	Buy	125 500	Stock Option (right to buy)

INSIDER POWER
41.90
Last 100 transactions
Buy: 2 399 671 \| Sell: 963 791

Volumen Correlación

Largo: -0.18 (neutral)

Corto: -0.56 (weak negative)

Signal:(45.355) Neutral

IDEAYA Biosciences Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IDEAYA Biosciences Inc Correlación - Moneda/Commodity

-0.62
( weak negative )

-0.76
( moderate negative )

0.06
( neutral )

-0.68
( moderate negative )

0.91
( very strong )

0.13
( neutral )

IDEAYA Biosciences Inc Finanzas

Annual	2023
Ingresos:	$23.39M
Beneficio Bruto:	$19.38M (82.86 %)
EPS:	$-1.960

FY	2023
Ingresos:	$23.39M
Beneficio Bruto:	$19.38M (82.86 %)
EPS:	$-1.960

FY	2022
Ingresos:	$50.93M
Beneficio Bruto:	$48.83M (95.87 %)
EPS:	$-1.320

FY	2021
Ingresos:	$27.94M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.410

Financial Reports:

No articles found.

IDEAYA Biosciences Inc

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.